Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GLX1112
- Development stage
- Preclinical
- Lead developer
- Glialogix
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
**GLX1112** is an improved, reformulated version of an FDA-approved drug developed by Glialogix for progressive multiple sclerosis (MS). It acts as a first-in-class neuroprotective agent that has demonstrated efficacy in slowing disability progression in progressive MS patients, with preclinical studies funded by the National MS Society's Fast Forward. The company is also exploring secondary indications including amyotrophic lateral sclerosis (ALS) and testing in Alzheimer's disease mouse models by antagonizing a novel target, though clinical trials have not yet begun as of available data.
- Other names
- GLX-1112GLX1112GLX 1112
Beyond the preview
Go deeper on GLX1112.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GLX1112.